Transactions
$550 Million
Co-Manager
Senior Note Offering
January 2022
$190 Million
Joint Bookrunner
Initial Public Offering
January 2022
UNDISCLOSED
Exclusive Financial Advisor
Divestiture of Baclofen Franchise to Amneal Pharmaceuticals
Pending
UNDISCLOSED
Financial Advisor
Merger with Pharm-Olam
January 2022
UNDISCLOSED
Financial Advisor
Merger with The Lynx Group
January 2022
$400 Million
Joint Bookrunner
Follow-On
January 2022
$150 Million
Sole Agent
At-The-Market (ATM) Facility
January 2022
UNDISCLOSED
Exclusive Financial Advisor
Acquisition of Majority Stake in Allergy Partners
December 2021
$125 Million
Exclusive Financial Advisor
Senior Secured Credit Facility with Pharmakon Advisors, LP
December 2021
$100 Million
Exclusive Financial Advisor
Series B Financing
December 2021
UNDISCLOSED
Exclusive Sell Side Advisor
Sale to Moody's
December 2021
$33 Million
Exclusive Placement Agent
Private Placement
December 2021
- « Previous Page
- Page 1
- Page 2
- Page 3
- ...
- Page 72
- Next Page »